Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01247818 · ClinicalTrials.gov registry record · Phase 2
Randomized Study of PH-10 for Psoriasis
A Phase 2 study of Psoriasis, sponsored by Provectus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 4
- Study locations
NCT01247818 is a Phase 2 study of Psoriasis that has completed, run by Provectus Pharmaceuticals. The registered enrollment target is 99 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01247818, a Phase 2 study of Psoriasis, has completed, sponsored by Provectus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 4
- Study locations
Study Summary
PH-10 is an aqueous hydrogel formulation of rose bengal disodium (RB) for topical administration to the skin, and is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. This multicenter phase 2 study of subjects randomized sequentially by center to one of four treatment cohorts will assess efficacy and safety of topical PH-10 applied once daily to areas of mild to moderate plaque psoriasis.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG PH-10 (0.002% Rose Bengal)
- DRUG PH-10 (0.005% Rose Bengal)
- DRUG PH-10 (0.01% Rose Bengal)
Study Locations (4)
California
- Dermatology Specialists, Inc. - Oceanside
Florida
- International Dermatology Research - Miami
New York
- Mount Sinai School of Medicine - New York
North Carolina
- Wake Research Associates - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01247818
The ClinicalTrials.gov registry entry for NCT01247818 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (80% lower). The listed sponsor is Provectus Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 4 interventions - of which Vehicle is the first listed.
NCT01247818 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT01247818 about?
NCT01247818 is a clinical study titled "Randomized Study of PH-10 for Psoriasis". PH-10 is an aqueous hydrogel formulation of rose bengal disodium (RB) for topical administration to the skin, and is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. This multicenter phase 2 study of subjects randomized sequentially by center...
What is the current status of trial NCT01247818?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2010-12. Estimated completion is 2012-03.
What conditions does trial NCT01247818 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01247818?
The interventions under investigation include: Vehicle (DRUG), PH-10 (0.002% Rose Bengal) (DRUG), PH-10 (0.005% Rose Bengal) (DRUG), PH-10 (0.01% Rose Bengal) (DRUG).
Who is sponsoring clinical trial NCT01247818?
This trial is sponsored by Provectus Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01247818 being conducted?
This trial has 4 study locations across California, Florida, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
Etanercept With Tacrolimus for Psoriasis
COMPLETED · Phase 2
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.